S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Rigel Pharmaceuticals Stock Forecast, Price & News

-0.15 (-5.14%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.82 million shs
Average Volume
2.39 million shs
Market Capitalization
$473.69 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Rigel Pharmaceuticals logo

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.


Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
November 15, 2021 |  finance.yahoo.com
Rigel to Participate in Two Upcoming Investor Conferences
November 9, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$108.62 million
Book Value
$0.29 per share


Net Income
$-29.74 million
Pretax Margin




Free Float
Market Cap
$473.69 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

1.99 out of 5 stars

Medical Sector

614th out of 1,391 stocks

Pharmaceutical Preparations Industry

283rd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

Is Rigel Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rigel Pharmaceuticals stock.
View analyst ratings for Rigel Pharmaceuticals
or view top-rated stocks.

How has Rigel Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RIGL shares have increased by 53.0% and is now trading at $2.77.
View which stocks have been most impacted by COVID-19

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Rigel Pharmaceuticals

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.02. The biotechnology company earned $21.54 million during the quarter, compared to the consensus estimate of $24.16 million. Rigel Pharmaceuticals had a negative net margin of 9.85% and a negative trailing twelve-month return on equity of 25.22%. During the same quarter last year, the company earned ($0.08) EPS.
View Rigel Pharmaceuticals' earnings history

What price target have analysts set for RIGL?

2 Wall Street analysts have issued twelve-month price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $9.50 in the next year. This suggests a possible upside of 243.0% from the stock's current price.
View analysts' price targets for Rigel Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the following people:
  • Raul R. Rodriguez, President, Chief Executive Officer & Director
  • Dean L. Schorno, Chief Financial Officer & Executive Vice President
  • Wolfgang Dummer, Chief Medical Officer & Executive Vice President
  • David Santos, Chief Commercial Officer & Executive VP
  • Joseph Lasaga, Senior Vice President-Corporate Development

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals CEO Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among Rigel Pharmaceuticals' employees.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.78%), Invesco Ltd. (3.03%), Rock Springs Capital Management LP (2.80%), Lord Abbett & CO. LLC (2.56%), Millennium Management LLC (2.37%) and Geode Capital Management LLC (1.82%).
View institutional ownership trends for Rigel Pharmaceuticals

Which major investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Millennium Management LLC, Citigroup Inc., Morgan Stanley, Schonfeld Strategic Advisors LLC, Oppenheimer & Co. Inc., Panagora Asset Management Inc., and Two Sigma Investments LP.
View insider buying and selling activity for Rigel Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Rigel Pharmaceuticals stock?

RIGL stock was acquired by a variety of institutional investors in the last quarter, including HealthInvest Partners AB, Laurion Capital Management LP, Dimensional Fund Advisors LP, Great Point Partners LLC, Goldman Sachs Group Inc., Hudson Bay Capital Management LP, Brandywine Global Investment Management LLC, and Summit Global Investments.
View insider buying and selling activity for Rigel Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $2.77.

How much money does Rigel Pharmaceuticals make?

Rigel Pharmaceuticals has a market capitalization of $473.69 million and generates $108.62 million in revenue each year. The biotechnology company earns $-29.74 million in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals employs 169 workers across the globe.

When was Rigel Pharmaceuticals founded?

Rigel Pharmaceuticals was founded in 1996.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is www.rigel.com.

Where are Rigel Pharmaceuticals' headquarters?

Rigel Pharmaceuticals is headquartered at 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 624-1100, via email at [email protected], or via fax at 650-624-1101.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.